Trial Profile

Phase 2a clinical trial of AP-188 in acute ischemic stroke patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs N-N-dimethyltryptamine (Primary)
Indications Stroke
Focus Therapeutic Use
Acronyms STROKE Study
Sponsors Algernon Pharmaceuticals

Most Recent Events

11 Feb 2025 According to an Algernon Pharmaceuticals media release, company has appointed Dr. Sandor Nardai as the Principal Investigator (PI) for its upcoming randomized, double-blind, placebo-controlled Phase 2a DMT study of 40 stroke patients in Europe. The study is expected to begin enrolling patients in Q3 of 2025.
05 Feb 2025 According to an Algernon Pharmaceuticals media release, this study is expected to begin enrolling patients in Q3 of 2025.
24 Apr 2024 According to an Algernon Pharmaceuticals media release, company plans to begin a Phase 2a clinical trial in acute ischemic stroke patients in 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com